Tom 19, Nr 3 (2023)
Artykuł przeglądowy
Opublikowany online: 2023-10-04
Wyświetlenia strony 558
Wyświetlenia/pobrania artykułu 316
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Choroba Fabry'ego — dlaczego warto ją poznać?

Agata Gajos1, Jarosław Sławek23
Pol. Przegl. Neurol 2023;19(3):202-215.

Streszczenie

Choroba Fabry’ego należy do ultrarzadkich chorób metabolicznych (lizosomalnych, spichrzeniowych) z zajęciem wielu narządów (nerki, serce, oko, mózg, nerwy obwodowe). Neurolog może mieć z nią do czynienia w przypadku udaru mózgu w młodym wieku bądź okresowych, napadowych kryz bólowych (bolesnej neuropatii obwodowej). Powiązanie objawów neurologicznych z zajęciem innych narządów może być kluczem do sukcesu diagnostycznego. Podejrzenie choroby można potwierdzić w łatwym do wykonania teście suchej kropli krwi, a ostatecznie w badaniu genetycznym. Jest to niezwykle ważne, ponieważ od kilkunastu lat dostępne jest leczenie tej choroby hamujące gromadzenie się nieprawidłowych metabolitów w docelowych tkankach. W Polsce jest ono dostępne i refundowane w ramach programu lekowego B.104. W celu uniknięcia trwałych uszkodzeń konieczne jest wczesne rozpoznanie, a zatem także czujność diagnostyczna w przypadkach charakterystycznych objawów. Autorzy w artykule omawiają patogenezę, najważniejsze objawy i zasady diagnostyki oraz metody leczenia, z uwzględnieniem zasad terapii w ramach programu lekowego obowiązującego w Polsce.

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Tuttolomondo A, Pecoraro R, Simonetta I, et al. Anderson-Fabry disease: a multiorgan disease. Curr Pharm Des. 2013; 19(33): 5974–5996.
  2. MacDermot KD, Holmes A, Miners AH. Natural history of Fabry disease in affected males and obligate carrier females. J Inherit Metab Dis. 2001; 24 Suppl 2: 13–4; discussion 11.
  3. Viggiano E, Politano L. X Chromosome Inactivation in Carriers of Fabry Disease: Review and Meta-Analysis. Int J Mol Sci. 2021; 22(14).
  4. Yoshimitsu M, Higuchi K, Miyata M, et al. Identification of novel mutations in the α-galactosidase A gene in patients with Fabry disease: pitfalls of mutation analyses in patients with low α-galactosidase A activity. J Cardiol. 2011; 57(3): 345–353.
  5. Fabry mutants list. http://fabry-database.org/mutants/ (May 24, 2023).
  6. Echevarria L, Benistan K, Toussaint A, et al. X-chromosome inactivation in female patients with Fabry disease. Clin Genet. 2016; 89(1): 44–54.
  7. Limongelli G, Nunziato M, D'Argenio V, et al. Yield and clinical significance of genetic screening in elite and amateur athletes. Eur J Prev Cardiol. 2021; 28(10): 1081–1090.
  8. Germain DP, Benistan K, Angelova L. X-linked inheritance and its implication in the diagnosis and management of female patients in Fabry disease. Rev Med Interne. 2010; 31 Suppl 2: S209–S213.
  9. Amodio F, Caiazza M, Monda E, et al. An Overview of Molecular Mechanisms in Fabry Disease. Biomolecules. 2022; 12(10).
  10. Ortiz A, Germain DP, Desnick RJ, et al. Fabry disease revisited: Management and treatment recommendations for adult patients. Mol Genet Metab. 2018; 123(4): 416–427.
  11. Nowicki M, Komar M, Kusztal M, et al. First two years of reimbursed enzyme replacement therapy in the treatment of Fabry disease in Poland. F1000Res. 2021; 10: 841.
  12. Ranieri M, Bedini G, Parati EA, et al. Fabry Disease: Recognition, Diagnosis, and Treatment of Neurological Features. Curr Treat Options Neurol. 2016; 18(7): 33.
  13. Aerts JM, Groener JE, Kuiper S, et al. Elevated globotriaosylsphingosine is a hallmark of Fabry disease. Proc Natl Acad Sci U S A. 2008; 105(8): 2812–2817.
  14. Schiffmann R, Rapkiewicz A, Abu-Asab M, et al. Pathological findings in a patient with Fabry disease who died after 2.5 years of enzyme replacement. Virchows Arch. 2006; 448(3): 337–343.
  15. Okeda R, Nisihara M. An autopsy case of Fabry disease with neuropathological investigation of the pathogenesis of associated dementia. Neuropathology. 2008; 28(5): 532–540.
  16. Cocozza S, Russo C, Pontillo G, et al. Neuroimaging in Fabry disease: current knowledge and future directions. Insights Imaging. 2018; 9(6): 1077–1088.
  17. Moore DF, Altarescu G, Barker WC, et al. White matter lesions in Fabry disease occur in 'prior' selectively hypometabolic and hyperperfused brain regions. Brain Res Bull. 2003; 62(3): 231–240.
  18. Rombach SM, Twickler ThB, Aerts JM, et al. Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab. 2010; 99(2): 99–108.
  19. Sims K, Politei J, Banikazemi M, et al. Stroke in Fabry disease frequently occurs before diagnosis and in the absence of other clinical events: natural history data from the Fabry Registry. Stroke. 2009; 40(3): 788–794.
  20. Mehta A, Ginsberg L. FOS Investigators. Natural history of the cerebrovascular complications of Fabry disease. Acta Paediatr Suppl. 2005; 94(447): 24–7; discussion 9.
  21. Kolodny E, Fellgiebel A, Hilz MJ, et al. Cerebrovascular involvement in Fabry disease: current status of knowledge. Stroke. 2015; 46(1): 302–313.
  22. Kono Yu, Wakabayashi T, Kobayashi M, et al. Characteristics of Cerebral Microbleeds in Patients with Fabry Disease. J Stroke Cerebrovasc Dis. 2016; 25(6): 1320–1325.
  23. Reisin RC, Romero C, Marchesoni C, et al. Brain MRI findings in patients with Fabry disease. J Neurol Sci. 2011; 305(1-2): 41–44.
  24. Fellgiebel A, Müller MJ, Ginsberg L. CNS manifestations of Fabry's disease. Lancet Neurol. 2006; 5(9): 791–795.
  25. Rolfs A, Böttcher T, Zschiesche M, et al. Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study. Lancet. 2005; 366(9499): 1794–1796.
  26. Rolfs A, Fazekas F, Grittner U, et al. Stroke in Young Fabry Patients (sifap) Investigators. Acute cerebrovascular disease in the young: the Stroke in Young Fabry Patients study. Stroke. 2013; 44(2): 340–349.
  27. Malavera A, Cadilhac DA, Thijs V, et al. Screening for Fabry Disease in Young Strokes in the Australian Stroke Clinical Registry (AuSCR). Front Neurol. 2020; 11: 596420.
  28. Tomek A, Petra R, Paulasová Schwabová J, et al. National Stroke Research Network, part of Czech Clinical Research Infrastructure Network (CZECRIN) and Czech Neurological Society, Cerebrovascular Section. Nationwide screening for Fabry disease in unselected stroke patients. PLoS One. 2021; 16(12): e0260601.
  29. Namer B, Ørstavik K, Schmidt R, et al. Changes in Ionic Conductance Signature of Nociceptive Neurons Underlying Fabry Disease Phenotype. Front Neurol. 2017; 8: 335.
  30. Albano B, Dinia L, Del Sette M, et al. Fabry disease in patients with migraine with aura. Neurol Sci. 2010; 31 Suppl 1: S167–S169.
  31. Sakurai Y, Kojima H, Shiwa M, et al. The hearing status in 12 female and 15 male Japanese Fabry patients. Auris Nasus Larynx. 2009; 36(6): 627–632.
  32. Köping M, Shehata-Dieler W, Schneider D, et al. Characterization of vertigo and hearing loss in patients with Fabry disease. Orphanet J Rare Dis. 2018; 13(1): 137.
  33. Wise AH, Yang A, Naik H, et al. Parkinson's disease prevalence in Fabry disease: A survey study. Mol Genet Metab Rep. 2018; 14: 27–30.
  34. Gago MF, Azevedo O, Guimarães A, et al. Parkinson's Disease and Fabry Disease: Clinical, Biochemical and Neuroimaging Analysis of Three Pedigrees. J Parkinsons Dis. 2020; 10(1): 141–152.
  35. Lackova A, Beetz C, Oppermann S, et al. Prevalence of Fabry Disease among Patients with Parkinson's Disease. Parkinsons Dis. 2022; 2022: 1014950.
  36. Mendez MF, Stanley TM, Medel NM, et al. The vascular dementia of Fabry's disease. Dement Geriatr Cogn Disord. 1997; 8(4): 252–257.
  37. Cole AL, Lee PJ, Hughes DA, et al. Depression in adults with Fabry disease: a common and under-diagnosed problem. J Inherit Metab Dis. 2007; 30(6): 943–951.
  38. Bolsover FE, Murphy E, Cipolotti L, et al. Cognitive dysfunction and depression in Fabry disease: a systematic review. J Inherit Metab Dis. 2014; 37(2): 177–187.
  39. Schermuly I, Müller MJ, Müller KM, et al. Neuropsychiatric symptoms and brain structural alterations in Fabry disease. Eur J Neurol. 2011; 18(2): 347–353.
  40. Duning T, Deppe M, Keller S, et al. Excessive Daytime Sleepiness Is a Common Symptom in Fabry Disease. Case Rep Neurol. 2009; 1(1): 33–40.
  41. Löhle M, Hughes D, Milligan A, et al. Clinical prodromes of neurodegeneration in Anderson-Fabry disease. Neurology. 2015; 84(14): 1454–1464.
  42. Rost NS, Cloonan L, Kanakis AS, et al. Determinants of white matter hyperintensity burden in patients with Fabry disease. Neurology. 2016; 86(20): 1880–1886.
  43. Moore DF, Altarescu G, Herscovitch P, et al. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease. BMC Neurol. 2002; 2: 4.
  44. Politei JM, Capizzano AA. Magnetic resonance image findings in 5 young patients with Fabry disease. Neurologist. 2006; 12(2): 103–105.
  45. Eng CM, Fletcher J, Wilcox WR, et al. Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry. J Inherit Metab Dis. 2007; 30(2): 184–192.
  46. Böttcher T, Rolfs A, Tanislav C, et al. Fabry disease - underestimated in the differential diagnosis of multiple sclerosis? PLoS One. 2013; 8(8): e71894.
  47. Fellgiebel A, Keller I, Martus P, et al. Basilar artery diameter is a potential screening tool for Fabry disease in young stroke patients. Cerebrovasc Dis. 2011; 31(3): 294–299.
  48. Manara R, Carlier RY, Righetto S, et al. Basilar Artery Changes in Fabry Disease. AJNR Am J Neuroradiol. 2017; 38(3): 531–536.
  49. Fazekas F, Enzinger C, Schmidt R, et al. SIFAP 1 Investigators. Brain magnetic resonance imaging findings fail to suspect Fabry disease in young patients with an acute cerebrovascular event. Stroke. 2015; 46(6): 1548–1553.
  50. Thijs V, Grittner U, Fazekas F, et al. Stroke in Fabry (SIFAP1) Investigators. Dolichoectasia and Small Vessel Disease in Young Patients With Transient Ischemic Attack and Stroke. Stroke. 2017; 48(9): 2361–2367.
  51. Prüss H, Bohner G, Zschenderlein R. Paroxysmal vertigo as the presenting symptom of Fabry disease. Neurology. 2006; 66(2): 249.
  52. Rombach SM, Twickler ThB, Aerts JM, et al. Vasculopathy in patients with Fabry disease: current controversies and research directions. Mol Genet Metab. 2010; 99(2): 99–108.
  53. Sacconi S, Bocquet JD, Chanalet S, et al. Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe disease. J Neurol. 2010; 257(10): 1730–1733.
  54. Takanashi Ji, Barkovich AJ, Dillon WP, et al. T1 hyperintensity in the pulvinar: key imaging feature for diagnosis of Fabry disease. AJNR Am J Neuroradiol. 2003; 24(5): 916–921.
  55. Fellgiebel A, Müller MJ, Ginsberg L. CNS manifestations of Fabry's disease. Lancet Neurol. 2006; 5(9): 791–795.
  56. Lehoux S, Castier Y, Tedgui A. Molecular mechanisms of the vascular responses to haemodynamic forces. J Intern Med. 2006; 259(4): 381–392.
  57. Shah JS, Hughes DA, Tayebjee MH, et al. Extracellular matrix turnover and disease severity in Anderson-Fabry disease. J Inherit Metab Dis. 2007; 30(1): 88–95.
  58. Lee HJ, Hung SC, Hsu TR, et al. Brain MR Imaging Findings of Cardiac-Type Fabry Disease with an IVS4+919G>A Mutation. AJNR Am J Neuroradiol. 2016; 37(6): 1044–1049.
  59. Renard D, Castelnovo G, Campello C, et al. Thalamic lesions: a radiological review. Behav Neurol. 2014; 2014: 154631.
  60. Jehn U, Bayraktar S, Pollmann S, et al. α-Galactosidase a Deficiency in Fabry Disease Leads to Extensive Dysregulated Cellular Signaling Pathways in Human Podocytes. Int J Mol Sci. 2021; 22(21).
  61. Froissart R, Guffon N, Vanier MT, et al. Fabry disease: D313Y is an alpha-galactosidase A sequence variant that causes pseudodeficient activity in plasma. Mol Genet Metab. 2003; 80(3): 307–314.
  62. Daitx VV, Mezzalira J, Goldim MP, et al. Comparison between alpha-galactosidase A activity in blood samples collected on filter paper, leukocytes and plasma. Clin Biochem. 2012; 45(15): 1233–1238.
  63. Khan A, Sirrs SM, Bichet DG, et al. Canadian Fabry Disease Initiative. The Safety of Agalsidase Alfa Enzyme Replacement Therapy in Canadian Patients with Fabry Disease Following Implementation of a Bioreactor Process. Drugs R D. 2021; 21(4): 385–397.
  64. Lukacs Z, Keil A, Kohlschütter A, et al. The ratio of alpha-galactosidase to beta-glucuronidase activities in dried blood for the identification of female Fabry disease patients. J Inherit Metab Dis. 2005; 28(5): 803–805.
  65. Togawa T, Kodama T, Suzuki T, et al. Plasma globotriaosylsphingosine as a biomarker of Fabry disease. Mol Genet Metab. 2010; 100(3): 257–261.
  66. Duro G, Zizzo C, Cammarata G, et al. Mutations in the GLA Gene and LysoGb3: Is It Really Anderson-Fabry Disease? Int J Mol Sci. 2018; 19(12).
  67. Yamashita S, Saotome M, Satoh H, et al. Plasma Globotriaosylsphingosine Level as a Primary Screening Target for Fabry Disease in Patients With Left Ventricular Hypertrophy. Circ J. 2019; 83(9): 1901–1907.
  68. Nowak A, Mechtler T, Kasper DC, et al. Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease. Mol Genet Metab. 2017; 121(4): 320–324.
  69. Baydakova GV, Ilyushkina AA, Moiseev S, et al. α-Galactosidase A/lysoGb3 ratio as a potential marker for Fabry disease in females. Clin Chim Acta. 2020; 501: 27–32.
  70. Smid BE, van der Tol L, Biegstraaten M, et al. Plasma globotriaosylsphingosine in relation to phenotypes of Fabry disease. J Med Genet. 2015; 52(4): 262–268.
  71. Michaud M, Mauhin W, Belmatoug N, et al. When and How to Diagnose Fabry Disease in Clinical Pratice. Am J Med Sci. 2020; 360(6): 641–649.
  72. Smid BE, van der Tol L, Cecchi F, et al. Uncertain diagnosis of Fabry disease: consensus recommendation on diagnosis in adults with left ventricular hypertrophy and genetic variants of unknown significance. Int J Cardiol. 2014; 177(2): 400–408.
  73. van der Tol L, Cassiman D, Houge G, et al. Uncertain diagnosis of fabry disease in patients with neuropathic pain, angiokeratoma or cornea verticillata: consensus on the approach to diagnosis and follow-up. JIMD Rep. 2014; 17: 83–90.
  74. Wang RY, Bodamer OA, Watson MS, et al. ACMG Work Group on Diagnostic Confirmation of Lysosomal Storage Diseases. Lysosomal storage diseases: diagnostic confirmation and management of presymptomatic individuals. Genet Med. 2011; 13(5): 457–484.
  75. Gal A, Beck M, Höppner W, et al. Clinical utility gene card for: Fabry disease - update 2016. Eur J Hum Genet. 2017; 25(7): e1–e3.
  76. Schiffmann R, Fuller M, Clarke LA, et al. Is it Fabry disease? Genet Med. 2016; 18(12): 1181–1185.
  77. Niemann M, Rolfs A, Störk S, et al. Gene mutations versus clinically relevant phenotypes: lyso-Gb3 defines Fabry disease. Circ Cardiovasc Genet. 2014; 7(1): 8–16.
  78. Nowicki M, Bazan-Socha S, Błażejewska-Hyzorek B, et al. Enzyme replacement therapy in Fabry disease in Poland: a position statement. Pol Arch Intern Med. 2020; 130(1): 91–97.
  79. El Dib R, Gomaa H, Ortiz A, et al. Enzyme replacement therapy for Anderson-Fabry disease: A complementary overview of a Cochrane publication through a linear regression and a pooled analysis of proportions from cohort studies. PLoS One. 2017; 12(3): e0173358.
  80. Feldt-Rasmussen U, Hughes D, Sunder-Plassmann G, et al. Long-term efficacy and safety of migalastat treatment in Fabry disease: 30-month results from the open-label extension of the randomized, phase 3 ATTRACT study. Mol Genet Metab. 2020; 131(1-2): 219–228.
  81. McCafferty EH, Scott LJ. Migalastat: A Review in Fabry Disease. Drugs. 2019; 79(5): 543–554.
  82. Politei JM, Bouhassira D, Germain DP, et al. Pain in Fabry Disease: Practical Recommendations for Diagnosis and Treatment. CNS Neurosci Ther. 2016; 22(7): 568–576.
  83. Kargiotis O, Psychogios K, Safouris A, et al. Intravenous Thrombolysis For Acute Ischemic Stroke in Fabry Disease. Neurologist. 2019; 24(5): 146–149.
  84. Ciba-Stemplewska A, Krzos D, Wożakowska-Kapłon B. Choroba Fabry’ego — długa droga do prawidłowego rozpoznania u 43-letniego chorego „Dr Google” nie zawsze taki zły... Folia Cardiologica. 2020; 15(2): 169–172.